7 Results for "

Structure-based

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Structure-based" in MCE Product Catalog:

Cat. No.: HY-126247
CAS No.: 2375482-51-0
Purity:  99.57%
Target:  

Ras

Research Areas:  

Cancer

BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
loading...
    loading...
Cat. No.: HY-126247B
CAS No.: 2375482-49-6
Purity:  97.32%
Target:  

Drug Derivative Ras

Research Areas:  

Cancer

(R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
loading...
    loading...
Cat. No.: HY-129886
CAS No.: 728886-01-9
Target:  

Antibiotic

Research Areas:  

Others

PKUMDL-LTQ-301 is a HipA toxin inhibitor discovered through structure-based virtual screening, which has the activity of significantly reducing the persistence of Escherichia coli. Its most effective compounds have certain KD and EC50 values when screened against different antibiotics in vitro and in vivo.
loading...
    loading...
Cat. No.: HY-180492
CAS No.: 24807-84-9
Research Areas:  

Cancer

NSC 121182 is a compound selected from NCI Diversity Set II by structure-based virtual screening. NSC 121182 can be used to study the Vitronectin-uPAR interaction. NSC 121182 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-187133
CAS No.: 2222-58-4
Target:  

Epoxide Hydrolase

Research Areas:  

Inflammation/Immunology

sEH-IN-26 is a urea structure-based soluble epoxide hydrolase (sEH) inhibitor with selectivity for mammalian cytosolic and peroxisomal sEH. sEH-IN-26 can be used for the research of inflammation and epoxide hydrolase-related diseases .
loading...
    loading...
Cat. No.: HY-W237439
CAS No.: 958712-85-1
Target:  

MDM-2/p53

Research Areas:  

Cancer

SEN205A is a fragment compound that binds to the hydrophobic pocket of human S100B (Kd=0.5-1.0 mM), which is the key region for the interaction of S100B with TRTK-12 and p53, and SEN205A can be displaced from this site by TRTK-12. SEN205A exhibits excellent in vitro ADME properties, including high metabolic stability, chemical stability, and good solubility under physiological pH conditions. SEN205A can serve as a starting fragment for structure-based optimization to develop inhibitors targeting the S100B-p53 protein-protein interaction and investigate the pathogenesis of malignant melanoma .
loading...
    loading...
Cat. No.: HY-E71188
Research Areas:  

Others

13-Deoxydaunorubicin hydroxylase (EC 1.14.13.181) shows broad substrate specificity for structures based on an anthracycline aglycone, but have a strong preference for 4-methoxy anthracycline intermediates (13-Deoxydaunorubicin and 13-dihydrodaunorubicin) over their 4-hydroxy analogues (13-deoxycarminomycin and 13-dihydrocarminomycin) , as well as a preference for substrates hydroxylated at the C-13 rather than the C-14 position.
loading...
    loading...